Abstract
Mirvaso is the first selective alpha2 agonist to be licensed in the UK for the management of the erythema of rosacea. Here we present the clinical data relating to its efficacy and adverse events and Dr Noreen Cowley comments on its place in therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
